Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells $131,939.93 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) COO Anish Patel sold 6,667 shares of the firm's stock in a transaction dated Monday, July 7th. The shares were sold at an average price of $19.79, for a total value of $131,939.93. Following the sale, the chief operating officer owned 296,642 shares in the company, valued at $5,870,545.18. The trade was a 2.20% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Anish Patel also recently made the following trade(s):

• On Monday, June 9th, Anish Patel sold 6,667 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.34, for a total value of $135,606.78.
• On Wednesday, May 7th, Anish Patel sold 6,667 shares of Enliven Therapeutics stock. The stock was sold at an average price of $18.39, for a total value of $122,606.13.

Enliven Therapeutics Trading Up 0.3%

NASDAQ:ELVN traded up $0.07 during trading hours on Friday, reaching $22.85. 115,628 shares of the company traded hands, compared to its average volume of 364,525. The business's 50-day moving average price is $19.67 and its two-hundred day moving average price is $20.30. The stock has a market capitalization of $1.12 billion, a P/E ratio of -11.90 and a beta of 0.83. Enliven Therapeutics, Inc. has a 1 year low of $13.30 and a 1 year high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.06). As a group, equities analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Institutional Trading of Enliven Therapeutics

A number of hedge funds have recently bought and sold shares of the company. FMR LLC increased its position in Enliven Therapeutics by 3.2% during the fourth quarter. FMR LLC now owns 6,495,871 shares of the company's stock valued at $146,157,000 after acquiring an additional 199,692 shares during the last quarter. Polar Capital Holdings Plc increased its position in Enliven Therapeutics by 267.6% during the fourth quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company's stock valued at $53,768,000 after acquiring an additional 1,739,668 shares during the last quarter. Vanguard Group Inc. grew its holdings in Enliven Therapeutics by 2.9% during the fourth quarter. Vanguard Group Inc. now owns 1,975,655 shares of the company's stock valued at $44,452,000 after purchasing an additional 55,283 shares during the period. Janus Henderson Group PLC grew its holdings in Enliven Therapeutics by 27.9% during the fourth quarter. Janus Henderson Group PLC now owns 1,331,877 shares of the company's stock valued at $30,001,000 after purchasing an additional 290,153 shares during the period. Finally, Pictet Asset Management Holding SA grew its holdings in Enliven Therapeutics by 16.3% during the fourth quarter. Pictet Asset Management Holding SA now owns 972,293 shares of the company's stock valued at $21,877,000 after purchasing an additional 135,969 shares during the period. Hedge funds and other institutional investors own 95.08% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on ELVN. Robert W. Baird lifted their price objective on Enliven Therapeutics from $40.00 to $52.00 and gave the stock an "outperform" rating in a report on Monday, June 16th. Jones Trading cut their price objective on Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating on the stock in a research report on Friday, May 16th. The Goldman Sachs Group initiated coverage on Enliven Therapeutics in a research report on Monday, June 16th. They issued a "buy" rating and a $37.00 price objective on the stock. Finally, HC Wainwright lifted their price objective on Enliven Therapeutics from $40.00 to $48.00 and gave the stock a "buy" rating in a research report on Wednesday, July 2nd. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $41.20.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.